KEYNOTE-061:胃食管腺癌中帕博利珠单抗与紫杉醇疗效的分子决定因素
KEYNOTE-061 III期随机试验探索性分析,在PD-L1 CPS≥1的胃/胃食管交界腺癌二线治疗中,评估组织肿瘤突变负荷(tTMB)与疗效的关系。全外显子测序(WES)数据可评估者420/592例(71%),tTMB在帕博利珠单抗组与ORR、PFS、OS显著相关(均P<0.001),紫杉醇组无显著关联(均P>0.6)。校正CPS后及排除MSI-H肿瘤后关联仍显著,提示tTMB是超越PD-L1的独立预测因素。
要点
- WES-tTMB与帕博利珠单抗的ORR、PFS、OS显著相关,与紫杉醇无关。
- tTMB与CPS相关性低(r≤0.16),校正CPS后关联仍显著。
- FoundationOne®CDx-tTMB与帕博利珠单抗疗效正相关,支持其临床应用。
核心结论
- 在胃/胃食管交界腺癌中,tTMB与帕博利珠单抗疗效强烈相关,而与紫杉醇无关。
- tTMB可能是超越PD-L1状态的显著且独立预测因素。
研究设计与样本
- KEYNOTE-061 III期随机开放标签试验(NCT02370498)的探索性分析。
- 纳入PD-L1 CPS≥1的胃/胃食管交界腺癌二线治疗患者。
- 有WES数据者420/592例(71%),帕博利珠单抗218例,紫杉醇202例;FoundationOne®CDx可评估205/592例(35%)。
- 预设等效截断值:WES 175 mut/exome,FoundationOne®CDx 10 mut/Mb。
主要发现
- 单因素分析中,WES-tTMB与帕博利珠单抗组的ORR、PFS、OS显著相关(均P<0.001),紫杉醇组无显著关联(均P>0.6)。
- WES-tTMB预测缓解的ROC曲线下面积:帕博利珠单抗组0.68(95%CI 0.56-0.81),紫杉醇组0.51(95%CI 0.39-0.63)。
- WES-tTMB与CPS在两个治疗组中相关性均低(r≤0.16)。
- 校正CPS后,WES-tTMB仍与帕博利珠单抗所有临床终点显著相关;排除已知MSI-H肿瘤(n=26)后,与PFS和OS仍显著相关。
- FoundationOne®CDx-tTMB与帕博利珠单抗组ORR、PFS、OS正相关(均P≤0.003),与紫杉醇组PFS或OS无关(P>0.1)。
临床怎么用
- tTMB可作为PD-L1之外独立预测帕博利珠单抗疗效的生物标志物。
- FoundationOne®CDx-tTMB(10 mut/Mb截断)与WES-tTMB(175 mut/exome)等效,支持临床检测。
- 对PD-L1 CPS≥1的胃/胃食管交界腺癌二线患者,tTMB有助于筛选帕博利珠单抗获益人群。
局限性
- 为探索性分析,WES数据仅覆盖71%患者,FoundationOne®CDx仅35%。
- 预设等效截断值需进一步验证。
- MSI-H肿瘤样本量小(n=26),排除后结论仍需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status. PATIENTS AND METHODS: In patients with whole exome sequencing (WES) data [420/592 (71%); pembrolizumab, 218; paclitaxel, 202], the association of tTMB with objective response rate (ORR; logistic regression), progression-free survival (PFS; Cox proportional hazards regression), and overall survival (OS; Cox proportional hazards regression) were measured using one-sided (pembrolizumab) and two-sided [paclitaxel] P values. tTMB was also evaluated using FoundationOne®CDx [205/592 (35%)]. Prespecified equivalent cut-offs of 175 mut/exome for WES and 10 mut/Mb for FoundationOne®CDx were used. RESULTS: WES-tTMB was significantly associated with ORR, PFS, and OS in pembrolizumab-treated (all P < 0.001) but not paclitaxel-treated patients (all P > 0.6) in univariate analysis. The area under the receiver operating characteristics curve for WES-tTMB and response was 0.68 [95% confidence interval (CI) 0.56-0.81] for pembrolizumab and 0.51 (95% CI 0.39-0.63) for paclitaxel in univariate analysis. There was low correlation between WES-tTMB and CPS in both treatment groups (r ≤ 0.16). WES-tTMB remained significantly associated with all clinical endpoints with pembrolizumab after adjusting for CPS and with PFS and OS after excluding known MSI-H tumors (n = 26). FoundationOne®CDx-tTMB demonstrated a positive association with ORR, PFS, and OS in pembrolizumab-treated patients (all P ≤ 0.003) but not PFS or OS in paclitaxel-treated patients (P > 0.1). CONCLUSION: This exploratory analysis from KEYNOTE-061 is the first to demonstrate a strong association between tTMB and efficacy with pembrolizumab but not paclitaxel in patients with gastric/GEJ adenocarcinoma in a randomized setting. Data further suggest tTMB is a significant and independent predictor beyond PD-L1 status.
引用
- Shitara K, Özgüroğlu M, Bang YJ, et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol. 2021. PMID: 34082019. doi:10.1016/j.annonc.2021.05.803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。